Jillian Acevedo‐Skrip

Merck & Co., Inc., Rahway, NJ, USA (United States)

Papers

1

Total Citations

6

H-Index

1

About

Dr. Jillian Acevedo-Skrip is a pioneering biotechnologist whose work sits at the critical intersection of analytical method development and mRNA vaccine safety. Her primary research focus is the characterization and quantitation of process-related impurities in nucleic acid therapeutics, a field essential to ensuring the potency and safety of next-generation vaccines. Her most impactful contribution to date is the development and application of an automated sandwich ELISA for the precise quantitation of residual double-stranded RNA (dsRNA) in mRNA vaccines. This work, published in 2024 and already garnering 6 citations, directly addresses a major manufacturing challenge: dsRNA is a common byproduct of the in vitro transcription reaction that can trigger unwanted immune responses and compromise vaccine efficacy. By creating a robust, high-throughput assay, Dr. Acevedo-Skrip has provided the industry with a critical tool for quality control, enabling more reliable and safer mRNA-based products. Her achievement is particularly notable for its immediate translational relevance, bridging the gap between fundamental analytical chemistry and real-world pharmaceutical production. As the mRNA platform continues to expand, her contributions to impurity profiling will remain foundational for both regulatory compliance and patient safety.

Research Focus

Key Achievements

1
H-Index
1
Papers
6
Total Citations
6
Avg Citations/Paper
🏆 Most Cited Paper
Development and Application of Automated Sandwich ELISA for Quantitating Residual dsRNA in mRNA Vaccines
6 citations · 2024
📈 Most Prolific Year: 2024 (1 Papers)
🤝 Key Collaborators: 9
🏛 Institutions: Merck & Co., Inc., Rahway, NJ, USA (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago